Trial Profile
An Open-Label Phase 2 Study of HQK-1001 in Subjects With Beta Thalassemia Intermedia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Mar 2014
Price :
$35
*
At a glance
- Drugs HQK 1001 (Primary)
- Indications Beta-thalassaemia
- Focus Pharmacogenomic; Therapeutic Use
- 21 Mar 2014 New trial record